search
Back to results

Intravascular Imaging- Versus Angiography-Guided Percutaneous Coronary Intervention For Complex Coronary Artery Disease (RENOVATE)

Primary Purpose

Coronary Artery Disease, Atherosclerosis

Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Percutaneous coronary intervention for complex lesion
Drug-eluting stent
Intravascular imaging (IVUS or OCT)
Drug-coated balloon
Sponsored by
Samsung Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring Intravascular Imaging, Intravascular Ultrasound, Optical Coherence Tomography, Complex Lesion, Percutaneous Coronary Intervention

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject age ≥19 years old
  • Coronary artery disease requiring PCI
  • Patients with complex lesion

    1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size
    2. Chronic total occlusion (≥3 months) as target lesion
    3. Unprotected LM disease PCI (LM ostium, body, distal LM bifurcation including non-true bifurcation)
    4. Long coronary lesions (implanted stent ≥38 mm in length)
    5. Multi-vessel PCI (≥2 vessels treated at one PCI session)
    6. Multiple stents needed (≥3 more stent per patient)
    7. In-stent restenosis lesion as target lesion
    8. Severely calcified lesion (encircling calcium in angiography)
    9. Ostial coronary lesion (LAD, LCX, RCA)
  • Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.

Exclusion Criteria:

  • Target lesions not amenable for PCI by operators' decision
  • Cardiogenic shock (Killip class IV) at presentation
  • Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
  • Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
  • Pregnancy or breast feeding
  • Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • Unwillingness or inability to comply with the procedures described in this protocol.

Sites / Locations

  • Samsung Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Intravascular imaging arm

Angiography arm

Arm Description

The choice of intravascular imaging devices such as IVUS or OCT during PCI will be left to the operator's discretion. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended. Use of intravascular imaging devices will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but intravascular imaging evaluation after stent implantation will be mandatory.

The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.

Outcomes

Primary Outcome Measures

Target vessel Failure
A composite of cardiac death, target vessel MI, and clinically-driven target vessel revascularization

Secondary Outcome Measures

Target vessel failure without procedure-related MI
A composite of cardiac death, spontaneous target vessel MI, and clinically-driven target vessel revascularization
Cardiac death or target-vessel related MI
Cardiac death or target-vessel related MI
All-cause death
any death
Cardiac death
cardiac death
Target vessel MI with procedure-related MI
Target vessel MI with procedure-related MI
Target vessel MI without procedure-related MI
Target vessel MI without procedure-related MI
Any MI with procedure-related MI
Any MI with procedure-related MI
Any MI without procedure-related MI
Any MI without procedure-related MI
Non-target vessel related MI
Non-target vessel related MI
Target lesion revascularization
TLR
Target vessel revascularization
TVR
Any revascularization
clinically-driven revascularization
Stent thrombosis
definite stent thrombosis
Incidence of contrast-induced nephropathy
CIN was defined as an increase in serum creatinine of ≥0.5mg/dL or ≥25% from baseline within 48-72 hours after contrast agent exposure
Total amount of contrast use
Total amount of contrast use during index hospitalization
Total procedure time
Total procedure time during index hospitalization
Total medical cost
Total medical cost

Full Information

First Posted
December 16, 2017
Last Updated
January 16, 2023
Sponsor
Samsung Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03381872
Brief Title
Intravascular Imaging- Versus Angiography-Guided Percutaneous Coronary Intervention For Complex Coronary Artery Disease
Acronym
RENOVATE
Official Title
Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention (RENOVATE-COMPLEX-PCI)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
May 10, 2018 (Actual)
Primary Completion Date
May 10, 2022 (Actual)
Study Completion Date
December 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Samsung Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the study is to compare clinical outcomes between intravascular imaging-guided versus angiography-guided percutaneous coronary intervention (PCI) in complex lesions.
Detailed Description
After introduction of the 2nd generation drug-eluting stents (DES), the rates of device-related failure or target lesion failure such as restenosis and stent thrombosis has been markedly decreased, compared with the era of bare metal stents or 1st generation DES. Nevertheless, patients undergoing percutaneous coronary intervention (PCI) for complex lesions, for example, chronic total occlusion (CTO), left main disease, true bifurcation lesion, long lesion, multi-vessel PCI, multiple overlapping stents, or severely calcified lesions have significantly worse clinical outcomes than those with non-complex lesions. During the PCI procedure, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are useful tools for providing information on preintervention lesion characteristics, including vulnerable plaques, lesion severity, length, and morphology; on postintervention optimal stent implantation for stent expansion, extension, and apposition; and on possible complications after stent implantation. Therefore, intravascular imaging guidance may improve clinical outcomes after complex PCI. However, although previous randomized controlled trial (RCT) and registries showed significantly lower rates of major adverse clinical events following IVUS-guided PCI compared with angiography-guided PCI, the RCTs were limited with small sample size and dealt with very selected lesion subsets such as CTO or long lesion. Moreover, it is uncertain whether OCT-guided PCI improves clinical outcomes compared with angiography-guided PCI. Meanwhile, appropriate imaging modality may differ according to patient and lesion characteristics. One of the ways to maximize the advantage of intravascular imaging is choice of intravascular imaging devices by the operator's discretion. Therefore, the current RENOVATE-COMPLEX-PCI (Randomized Controlled Trial of Intravascular Imaging Guidance versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) is designed to investigate whether PCI under guidance of intravascular imaging devices (IVUS or OCT) chosen by operators would improve clinical outcomes compared with angiography-guided PCI in patients with complex lesions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Atherosclerosis
Keywords
Intravascular Imaging, Intravascular Ultrasound, Optical Coherence Tomography, Complex Lesion, Percutaneous Coronary Intervention

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, open label, two-arm, randomized controlled trial
Masking
InvestigatorOutcomes Assessor
Masking Description
All end points will be independently adjudicated by Clinical Event Adjudication Committee (CEAC).
Allocation
Randomized
Enrollment
1639 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intravascular imaging arm
Arm Type
Active Comparator
Arm Description
The choice of intravascular imaging devices such as IVUS or OCT during PCI will be left to the operator's discretion. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended. Use of intravascular imaging devices will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but intravascular imaging evaluation after stent implantation will be mandatory.
Arm Title
Angiography arm
Arm Type
Active Comparator
Arm Description
The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
Intervention Type
Procedure
Intervention Name(s)
Percutaneous coronary intervention for complex lesion
Intervention Description
In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms Intravascular imaging arm Angiography arm Definition of Complex Lesions True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size Chronic total occlusion (≥3 months) as target lesion PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation) Implanted stent length ≥38mm Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session) Multiple stent needed (≥3 more stent per patient) In-stent restenosis lesion as target lesion Severely calcified lesion (encircling calcium in angiography) Ostial coronary lesion (LAD, LCX, RCA)
Intervention Type
Device
Intervention Name(s)
Drug-eluting stent
Intervention Description
All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
Intervention Type
Device
Intervention Name(s)
Intravascular imaging (IVUS or OCT)
Intervention Description
IVUS Reference site: Largest lumen, Plaque burden <50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: [1] By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25 mm. [2] By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25 mm.
Intervention Type
Device
Intervention Name(s)
Drug-coated balloon
Intervention Description
All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
Primary Outcome Measure Information:
Title
Target vessel Failure
Description
A composite of cardiac death, target vessel MI, and clinically-driven target vessel revascularization
Time Frame
1-year after last patient enrollment
Secondary Outcome Measure Information:
Title
Target vessel failure without procedure-related MI
Description
A composite of cardiac death, spontaneous target vessel MI, and clinically-driven target vessel revascularization
Time Frame
1-year after last patient enrollment
Title
Cardiac death or target-vessel related MI
Description
Cardiac death or target-vessel related MI
Time Frame
1-year after last patient enrollment
Title
All-cause death
Description
any death
Time Frame
1-year after last patient enrollment
Title
Cardiac death
Description
cardiac death
Time Frame
1-year after last patient enrollment
Title
Target vessel MI with procedure-related MI
Description
Target vessel MI with procedure-related MI
Time Frame
1-year after last patient enrollment
Title
Target vessel MI without procedure-related MI
Description
Target vessel MI without procedure-related MI
Time Frame
1-year after last patient enrollment
Title
Any MI with procedure-related MI
Description
Any MI with procedure-related MI
Time Frame
1-year after last patient enrollment
Title
Any MI without procedure-related MI
Description
Any MI without procedure-related MI
Time Frame
1-year after last patient enrollment
Title
Non-target vessel related MI
Description
Non-target vessel related MI
Time Frame
1-year after last patient enrollment
Title
Target lesion revascularization
Description
TLR
Time Frame
1-year after last patient enrollment
Title
Target vessel revascularization
Description
TVR
Time Frame
1-year after last patient enrollment
Title
Any revascularization
Description
clinically-driven revascularization
Time Frame
1-year after last patient enrollment
Title
Stent thrombosis
Description
definite stent thrombosis
Time Frame
1-year after last patient enrollment
Title
Incidence of contrast-induced nephropathy
Description
CIN was defined as an increase in serum creatinine of ≥0.5mg/dL or ≥25% from baseline within 48-72 hours after contrast agent exposure
Time Frame
48-72 hours after index procedure
Title
Total amount of contrast use
Description
Total amount of contrast use during index hospitalization
Time Frame
Immediate after index procedure
Title
Total procedure time
Description
Total procedure time during index hospitalization
Time Frame
Immediate after index procedure
Title
Total medical cost
Description
Total medical cost
Time Frame
1-year after last patient enrollment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject age ≥19 years old Coronary artery disease requiring PCI Patients with complex lesion True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size Chronic total occlusion (≥3 months) as target lesion Unprotected LM disease PCI (LM ostium, body, distal LM bifurcation including non-true bifurcation) Long coronary lesions (implanted stent ≥38 mm in length) Multi-vessel PCI (≥2 vessels treated at one PCI session) Multiple stents needed (≥3 more stent per patient) In-stent restenosis lesion as target lesion Severely calcified lesion (encircling calcium in angiography) Ostial coronary lesion (LAD, LCX, RCA) Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. Exclusion Criteria: Target lesions not amenable for PCI by operators' decision Cardiogenic shock (Killip class IV) at presentation Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock) Pregnancy or breast feeding Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment) Unwillingness or inability to comply with the procedures described in this protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joo-Yong Hahn, MD, PhD
Organizational Affiliation
Samsung Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked

Learn more about this trial

Intravascular Imaging- Versus Angiography-Guided Percutaneous Coronary Intervention For Complex Coronary Artery Disease

We'll reach out to this number within 24 hrs